Economic evaluation of vedolizumab SC for the treatment of moderate-to-severe ulcerative colitis in Canada

被引：0
作者：
Fischer, A. [1 ]
Oppe, M. [2 ]
Stypa, S. [1 ]
Lukyanov, V. [3 ]
Petrakis, I. [4 ]
机构：
[1] Takeda Canada Inc, Patient Value & Access, Toronto, ON, Canada
[2] Axent Solut, Pharmacoecon, San Cristobal la Laguna, Spain
[3] IQVIA, Real World Insights, Amsterdam, Netherlands
[4] Takeda Inc, Payer Value & Patient Access, Boston, MA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P424
引用
收藏
页码：S387 / S387
页数：1
相关论文
共 50 条
[41]   Efficacy and Safety of Vedolizumab in Management of Moderate to Severe Ulcerative Colitis: A Systematic Review [J].
Bhandari, Renu ;
Ogeyingbo, Opemipo D. ;
Kareem, Roaa ;
Gyawali, Mallika ;
Venkatesan, Nanditha ;
Ahmed, Rowan ;
Botleroo, Rinky A. ;
Elshaikh, Abeer O. .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (09)
[42]   Mirikizumab for the treatment of moderate to severe ulcerative colitis [J].
Hanzel, Jurij ;
Ma, Christopher ;
Jairath, Vipul .
IMMUNOTHERAPY, 2023, 15 (15) :1199-1208
[43]   Treatment algorithm for moderate to severe ulcerative colitis [J].
Manz, Michael ;
Michetti, Pierre ;
Seibold, Frank ;
Rogler, Gerhard ;
Beglinger, Christoph .
SWISS MEDICAL WEEKLY, 2011, 141
[44]   Transcriptional biomarkers for vedolizumab therapy response in patients with moderate to severe Ulcerative Colitis [J].
Arosa Garcia, L. ;
Camba-Gomez, M. ;
Calvino-Suarez, C. ;
Baston-Rey, I. ;
Ferreiro-Iglesias, R. ;
Porto, M. ;
Nieto-Garcia, L. ;
Dominguez-Munoz, J. E. ;
Barreiro-de Acosta, M. ;
Conde-Aranda, J. .
JOURNAL OF CROHNS & COLITIS, 2022, 16 :I147-I147
[45]   Vedolizumab for the treatment of ulcerative colitis [J].
Rietdijk, Svend T. ;
D'Haens, Geert R. .
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (04) :423-430
[46]   Vedolizumab for the treatment of ulcerative colitis [J].
Shahidi, Neal ;
Bressler, Brian ;
Panaccione, Remo .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (01) :129-135
[47]   CURRENT LANDSCAPE AND TREATMENTS USED IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS [J].
Siegel, C. A. ;
Seigel, L. ;
Verma, S. ;
Sruti, I ;
Mu, Q. ;
Gupte, K. .
VALUE IN HEALTH, 2021, 24 :S99-S99
[48]   TRANSCRIPTOMIC SIGNATURE OF RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM AN INTERNATIONAL, MULTICENTER, RETROSPECTIVE COHORT STUDY [J].
Linggi, Bryan ;
Salas, Azucena ;
Veny, Marisol ;
Borowski, Krzysztof ;
Silverberg, Mark S. ;
Milgrom, Raquel ;
Stempak, Joanne ;
Boland, Brigid ;
Eckmann, Lars ;
Smith, Michelle I. ;
Parker, Claire E. ;
Jairath, Vipul ;
Teft, Wendy ;
Vande Casteele, Niels .
GASTROENTEROLOGY, 2024, 166 (05) :S1114-S1114
[49]   Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada [J].
Fenu, Elisabetta ;
Lukyanov, Vasily ;
Acs, Annabel ;
Radu, Xenia ;
Stypa, Stephanie ;
Fischer, Aren ;
Marshall, John K. ;
Oppe, Mark .
PHARMACOECONOMICS-OPEN, 2022, 6 (04) :519-537
[50]   Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis [J].
Nakamura, Masanao ;
Yamamura, Takeshi ;
Maeda, Keiko ;
Sawada, Tsunaki ;
Mizutani, Yasuyuki ;
Ishikawa, Eri ;
Ishikawa, Takuya ;
Kakushima, Naomi ;
Furukawa, Kazuhiro ;
Ohno, Eizaburo ;
Kawashima, Hiroki ;
Honda, Takashi ;
Ishigami, Masatoshi ;
Fujishiro, Mitsuhiro .
NAGOYA JOURNAL OF MEDICAL SCIENCE, 2022, 84 (01) :169-179
12345